Oncotarget · 2018 · 60 citations · 20 references
MedicineNuclear MedicineOncologyDiagnostic ImagingImmunotherapyTumor ProgressionCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint ModulationImmune CheckpointsTumor CharacterizationCheckpoint Modulation In CancerDisease Progression VisualizationImage EnlargementImmune Checkpoint Inhibitor TherapyMetastatic Melanoma TreatmentMonitoring During Immune Checkpoint TherapyT Cell Checkpoint InhibitionTumor Progression Dynamics
// Svetomir N. Markovic 1, 4 , Filippo Galli 2 , Vera J. Suman 3 , Wendy K. Nevala 4 , Andrew M. Paulsen 5 , Joseph C. Hung 5 , Denise N. Gansen 5 , Lori A. Erickson 6 , Paolo Marchetti 7 , Gregory A. Wiseman 5 and Alberto Signore 2 1 Department of Oncology, Mayo Clinic, Rochester, MN, USA 2 Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, “Sapienza” University of Rome, Rome, Italy 3 Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA 4 Department of Immunology, Mayo Clinic, Rochester, MN, USA 5 Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA 6 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA 7 Oncology Unit, Department of Clinical and Molecular Medicine, “Sapienza” University of Rome, and IDI-IRCCS, Rome, Italy Correspondence to: Alberto Signore, email: alberto.signore@uniroma1.it Keywords: check point inhibitors; ipilimumab; pembrolizumab; melanoma; 99m Tc-IL2 Received: December 28, 2017 Accepted: June 04, 2018 Published: July 13, 2018 ABSTRACT Early in the course of immunotherapy there is frequently a transient enlargement of tumor masses (pseudo-progression) due to tumor infiltration by TILs. Current clinical imaging modalities are not able to distinguished pseudo-progression from true tumor progression. Thus, patients often remain on treatment 4-8 weeks longer to confirm disease progression. Nuclear medicine offers the possibility to image immune cells and potentially discriminate pseudo-progression and progression. We conducted a pilot study in patients with metastatic melanoma receiving ipilimumab (IPI) or pembrolizumab (PEMBRO) to assess safety and feasibility of SPECT/CT imaging with 99m Tc- interleukin-2 ( 99m Tc-HYNIC-IL2) to detect TILs and distinguish between true progression from pseudo- progression. Scans were performed prior to and after 12w treatment. After labelling, 99m Tc-HYNIC-IL2 was purified and diluted in 10 mL of 5% glucose with 0.1% human serum albumin. Of the 5 patients (2 treated with IPI and 3 with PEMBRO) enrolled, two failed to complete the second scan as they discontinued IPI due grade 3 colitis (1 patient) or patient refusal after developing multiple toxicities attributed to IPI (1 patient). Following the first scan, one patient reported to have a grade 1 pruritus with grade 1 pain. No other toxicities attributed to the radiopharmaceutical infusion were reported. Metastatic lesions could be visualized by 99m Tc-IL2 imaging and there was positive correlation between size and 99m Tc-HYNIC-IL2 uptake, both before and after 12 weeks of therapy. The results of this pilot study demonstrate the safety and feasibility of 99m Tc-IL2 imaging and has led to a number of hypotheses to be tested in future studies.
20
An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy
Richard Tavaré, Helena Escuin-Ordinas, Stephen Mok et al. · Cancer Research · 2015 · 325 citations · Full text
Medicine, Immunology, Oncology +17
<sup>89</sup>Zr-Oxine Complex PET Cell Imaging in Monitoring Cell-based Therapies
Noriko Sato, Haitao Wu, Kingsley O. Asiedu et al. · Radiology · 2015 · 153 citations
Medicine, Nuclear Medicine, Oncology +17